본문
SEOUL, Korea – L&C Bio (KOSDAQ: 290650) announced on the 13th that it participated as a key sponsor in the 67th Annual International Congress of the Korean Orthopaedic Association (KOA 2023).
Earlier this year, L&C Bio established L&C Medicare to expand its presence in the orthopedic market. At the KOA congress, the company showcased its flagship products including MegaDerm®, MegaDBM®, MegaBone®, STENInject®, and MegaDerm® XE, alongside new launches such as MegaCarti® and MegaNerve Prime®.
During the Luncheon Symposium, Professor Sung-Hwan Kim of Gangnam Severance Hospital delivered a keynote titled “The New Era for the Repair of the Knee Articular Cartilage,” introducing the clinical excellence and effectiveness of MegaCarti®. According to L&C Bio, this was the first official academic presentation of MegaCarti® since it became eligible for non-reimbursed clinical use, drawing significant attention.
CEO Hwan-Chul Lee stated:
“The approval of MegaCarti® marks a major milestone, especially for ICRS grade 3 patients who previously had limited treatment options.
We will continue to support key events such as KOA and collaborate on clinical research to advance orthopedic science and meet the needs of medical professionals.”
Founded in 1956, the Korean Orthopaedic Association consists of 7 regional branches, 18 specialty societies, and 8 affiliated associations. The 67th Congress was held from October 12 to 14.
